Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Total Non-Current Liabilities of $178.6 million for Q1 2026, down 24.24% year-over-year from $235.7 million in Q1 2025, and down 1.84% quarter-over-quarter from $181.9 million in Q4 2025.
Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $178.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 24.24% year-over-year to $178.6 million; the TTM figure through Mar 2026 stood at $178.6 million (down 24.24% YoY), while the FY2025 annual figure was $181.9 million, down 22.86% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $178.6 million, down from $181.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $416.2 million in Q1 2022, with the low at $178.6 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $262.4 million (2023), against an average of $277.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities decreased 9.01% in 2022, then declined 27.17% in 2023.
- Nektar Therapeutics' Total Non-Current Liabilities stood at $336.4 million in 2022, then decreased by 22.0% to $262.4 million in 2023, then retreated by 10.11% to $235.9 million in 2024, then fell by 22.86% to $181.9 million in 2025, then declined by 1.84% to $178.6 million in 2026.
- Business Quant data shows NKTR's Total Non-Current Liabilities at $178.6 million in Q1 2026, $181.9 million in Q4 2025, and $211.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 178.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178.61 Mn |
| Dec 31, 2025 | 181.95 Mn |
| Sep 30, 2025 | 211.24 Mn |
| Jun 30, 2025 | 226.11 Mn |
| Mar 31, 2025 | 235.75 Mn |
| Dec 31, 2024 | 235.87 Mn |
| Sep 30, 2024 | 252.17 Mn |
| Jun 30, 2024 | 255.60 Mn |
| Mar 31, 2024 | 264.97 Mn |
| Dec 31, 2023 | 262.41 Mn |
| Sep 30, 2023 | 277.92 Mn |
| Jun 30, 2023 | 292.17 Mn |
| Mar 31, 2023 | 314.40 Mn |
| Dec 31, 2022 | 336.41 Mn |
| Sep 30, 2022 | 368.78 Mn |
| Jun 30, 2022 | 401.18 Mn |
| Mar 31, 2022 | 416.23 Mn |
| Dec 31, 2021 | 434.09 Mn |
| Sep 30, 2021 | 454.32 Mn |
| Jun 30, 2021 | 462.36 Mn |